- Home
- SUPN vs NGD Comparison
SUPN vs NGD Comparison
Compare SUPN & NGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- NGD
- Stock Information
- Founded
- SUPN 2005
- NGD N/A
- Country
- SUPN United States
- NGD Canada
- Employees
- SUPN N/A
- NGD N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- NGD
- Sector
- SUPN Health Care
- NGD
- Exchange
- SUPN Nasdaq
- NGD Nasdaq
- Market Cap
- SUPN 2.0B
- NGD 2.0B
- IPO Year
- SUPN 2012
- NGD 2004
- Fundamental
- Price
- SUPN $35.66
- NGD $2.64
- Analyst Decision
- SUPN Hold
- NGD Buy
- Analyst Count
- SUPN 1
- NGD 4
- Target Price
- SUPN $36.00
- NGD $3.04
- AVG Volume (30 Days)
- SUPN 285.1K
- NGD 8.0M
- Earning Date
- SUPN 11-04-2024
- NGD 02-11-2025
- Dividend Yield
- SUPN N/A
- NGD N/A
- EPS Growth
- SUPN 130.79
- NGD N/A
- EPS
- SUPN 1.07
- NGD 0.02
- Revenue
- SUPN $651,972,000.00
- NGD $861,500,000.00
- Revenue This Year
- SUPN $7.82
- NGD $22.53
- Revenue Next Year
- SUPN N/A
- NGD $31.05
- P/E Ratio
- SUPN $34.11
- NGD $112.53
- Revenue Growth
- SUPN 6.79
- NGD 14.85
- 52 Week Low
- SUPN $25.53
- NGD $1.09
- 52 Week High
- SUPN $39.37
- NGD $3.25
- Technical
- Relative Strength Index (RSI)
- SUPN 48.87
- NGD 42.57
- Support Level
- SUPN $35.68
- NGD $2.78
- Resistance Level
- SUPN $37.35
- NGD $3.08
- Average True Range (ATR)
- SUPN 1.01
- NGD 0.11
- MACD
- SUPN -0.18
- NGD -0.02
- Stochastic Oscillator
- SUPN 21.65
- NGD 7.45
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.